AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Chimeric states that no patient exhibited any dose-limiting toxicities in the 3rd dose cohort in the Phase 1A CHM 1101 (CLTX CAR T) clinical trial.
- The Phase 1A trial is being studied in patients with MMP2+ recurrent or progressive glioblastoma.
- Following this positive outcome in 3rd dose cohort, the trial will now advance to the 4th and final dose cohort.
Australian leader in cell therapy Chimeric Therapeutics (ASX:CHM) recently provided a major update concerning its 3rd dose cohort in the Phase 1A CHM 1101 (CLTX CAR T) clinical trial. All the patients dosed in the 3rd patient cohort in the trial have progressed beyond the 28-day follow-up period without exhibiting any dose-limiting toxicities, highlights the company update.
The Phase 1A trial is being studied in MMP2+ recurrent or progressive glioblastoma. It aims to enrol 18-36 patients across four dose levels.
Below are the study objectives:
- Assessing CLTX CAR T safety and efficacy.
- For a phase 2 study, defining suggested dosing.
© 2023 Krish Capital Pty. Ltd, Image source: Company website, data source: Company update
The patients in the 3rd dose cohort were dosed at the City of Hope National Medical Center, and they received a total dose of 240 X 106 CHM 1101 (CLTX CAR T) cells.
City of Hope is one of the biggest cancer research and treatment organisations in the United States. It is leading the current Phase 1A CHM 1101 (CLTX CAR T) cell therapy clinical trial. Chimeric has licenced the exclusive global rights to intellectual property covering the chlorotoxin CAR-T cells from City of Hope.
Following this outcome, the trial will now advance to the 4th and final dose cohort, where patients will be given a total dose of 440 X 106 CHM 1101 CAR T cells. There is dual route of administration, intratumoral (ICT) and intraventricular (ICV), in both the cohorts.
CHM shares were trading at AU$0.080 midday on 30 January 2023.